Hematology

Study finds health-related quality of life is often not collected for novel cancer drugs when they are submitted for reimbursement.

Two cell mutations have been linked to acute myeloid leukemia, but the reason for their cooperation has been unknown.

Study shows the importance of a cancer-causing oncogene, known as SET/TAF1, in triggering cancer cell proliferation.

Daratumumab was approved based on results from part one of the Phase III CASSIOPEIA study.

Study indicated that patients who received radiation 30 days or fewer before their CAR T-cell infusion did not experience serious cytokine release syndrome or neurotoxicity.

Patients with diabetes demonstrated a higher likelihood of developing non-Hodgkin lymphoma than those without diabetes, especially among men.

Top news of the day from across the health care landscape.

Hematology and oncology pharmacists discussed patient outreach at a panel during the Hematology/Oncology Pharmacy Association’s (HOPA) annual conference in April.

A new study identified pathways that may serve as therapeutic targets for overcoming drug resistance in acute myeloid leukemia.

Immunotherapy methods emerged on the oncology market as adoptive cell transfers, specifically chimeric antigen receptor (CAR) T-cell therapies, with clear benefits in hematologic malignancy treatment.

On November 2018, the FDA approved Pfizer’s glasdegib (Daurismo) for the treatment of newly diagnosed acute myeloid leukemia (AML) in patients 75 years and older with comorbidities that prevent the use of intensive induction-dose chemotherapy.

The study findings suggest that, while the link between chronic lymphocytic leukemia and melanoma had been known, the rate at which the link occurs is higher than expected.

ABP 798, a biosimilar candidate to rituximab (Rituxan), demonstrated clinical equivalence in a study of patients with non-Hodgkin lymphoma.

Selinexor with dexamethasone effective in more than one-quarter of patients with multiple myeloma during a clinical trial.

Top news of the day from across the health care landscape.

Combination of ibrutinib and rituximab found to improve overall survival in patients with chronic lymphocytic leukemia.

Zanubrutinib, a Bruton’s tyrosine kinase inhibitor, is being evaluated in a broad pivotal clinical program across multiple B-cell malignancies.

Research highlights the importance of regular blood testing to impove earlier detection of multiple myeloma.

Study recommends similar clinical thresholds for diagnosing and managing giant cell arteritis for patients of different ethnicities.

The approval of fedratinib (Inrebic, Celgene) provides another treatment option for patients with myelofibrosis, a rare bone marrow disorder.

If approved, acalabrutinib (Calquence, AstraZeneca) will offer a chemotherapy-free treatment option for adults with chronic lymphocytic leukemia.

The number of first-degree relatives affected by blood cancer and age of diagnosis may contribute to the likelihood of a family member’s risk of being diagnosed with the same disease.

A recent study analyzed the 10-year absolute risks of thromboembolism and bleeding in patients with a history of hematologic cancer.

Selinexor (Xpovio, Karyopharm) received approval in combination with dexamethasone for heavily-pretreated patients with relapsed or refractory multiple myeloma.

Daratumumab (Darzalex, Janssen) is indicated for use in combination with lenalidomide and dexamethasone for patients with newly-diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.